

# Advancements in Ocular Regenerative Therapies

Wojciech Tomczak, Weronika Winkler-Lach, Martyna Tomczyk-Socha and Marta Misiuk-Hojło

Table S1. Summary of the nine clinical trials in retinal diseases.

Title	NCT number	Status	Design	Brief description	Age/group demographics	Conditions
<b>Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II</b>	NCT03011541	Recruiting	<ul style="list-style-type: none"> <li>Intervention Model: Single Group Assignment</li> <li>Intervention Model Description: Single Arm- Arm 1. Comparator is natural history of the disease.</li> <li>Masking: None (Open Label)</li> <li>Primary Purpose: Treatment</li> </ul>	Evaluating the use of autologous bone marrow-derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease	18 years and older	<ul style="list-style-type: none"> <li>Retinal Disease</li> <li>Age-Related Macular Degeneration</li> <li>Retinitis Pigmentosa</li> <li>Stargardt Disease</li> <li>Optic Neuropathy</li> <li>Nonarteritic Ischemic Optic Neuropathy</li> <li>Optic Atrophy</li> <li>Optic Nerve Disease</li> <li>Glaucoma</li> <li>Leber Hereditary Optic Neuropathy</li> <li>Blindness</li> <li>Vision Loss Night</li> <li>Vision Loss Partial</li> <li>Vision, Low</li> <li>Retinopathy</li> <li>Maculopathy</li> <li>Macular Degeneration</li> <li>Retina Atrophy</li> </ul>
<b>Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in</b>	NCT03288844	Active, not recruiting	<ul style="list-style-type: none"> <li>Multinational</li> <li>Multicentre</li> </ul>	A follow-up study of patients transplanted in the HOLOCORE clinical trial who consent to participate.	Adults and children	<ul style="list-style-type: none"> <li>Limbal Stem Cell Deficiency Due to Ocular Burn</li> </ul>

<b>Patients With LSCD Due to Ocular Burns</b>		<ul style="list-style-type: none"> <li>• Time perspective: Prospective</li> <li>• Primary Purpose: to collect long-term efficacy and safety data</li> </ul>			
<b>Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency</b>	NCT03949881 Recruiting	<ul style="list-style-type: none"> <li>• Intervention Model: Single Group Assignment</li> <li>• Masking: None (Open Label)</li> <li>• Primary Purpose: Treatment</li> </ul>	A clinical trial performed to evaluate tolerance and efficacy of the autologous jugal mucosa cell sheet cultured using innovative process.	18 years and older	• Total Bilateral Limbal Cell Deficiency
<b>Treatment of Central Retinal Vein Occlusion Using Stem Cells Study</b>	NCT03981549	<ul style="list-style-type: none"> <li>• Allocation: Randomized</li> <li>• Intervention Model: Parallel Assignment</li> <li>• Masking: Triple (Participant, Investigator, Outcomes Assessor)</li> <li>• Primary Purpose: Treatment</li> </ul>	To evaluate whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO).	18 years and older	• Central Retinal Vein Occlusion
<b>The Effects of Allogeneic Simple Limbal Epithelial Transplantation</b>	NCT04021134 Recruiting	<ul style="list-style-type: none"> <li>• Observational Model: Case-Only</li> <li>• Time Perspective: Prospective</li> <li>• Primary Purpose: assessing the SLET effectiveness</li> </ul>	To investigate the effect of allogeneic SLET and re-epithelialization after allogeneic SLET.	10 to 90 years old	• Limbal Stem-cell Deficiency
<b>Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells</b>	NCT05705024	<ul style="list-style-type: none"> <li>• Allocation: Randomized</li> <li>• Intervention Model: Parallel Assignment</li> <li>• Masking: Double (Participant, Care Provider)</li> <li>• Primary Purpose: Treatment</li> </ul>	The assessment of efficacy of locally delivered allogeneic mesenchymal stromal cells on chronic epitheliopathies.	18 years and older	• Corneal Ulcer

<b>Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease</b>	NCT03878628	Active, not recruiting	<ul style="list-style-type: none"> <li>•</li> <li>•</li> <li>•</li> </ul>	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	To assess the safety and feasibility of allogeneic adipose tissue-derived mesenchymal stem cells injected into the lacrimal gland in patients with Aqueous Deficient Dry Eye Disease.	18 years and older	<ul style="list-style-type: none"> <li>•</li> <li>•</li> </ul>	<ul style="list-style-type: none"> <li>• Dry Eye</li> <li>• Kerato Conjunctivitis Sicca</li> <li>• Aqueous Tear Deficiency</li> </ul>
<b>Ocular Graft-Versus-Host-Disease After Allogeneic Haematopoietic Stem Cell Transplantation</b>	NCT05170347	Recruiting	<ul style="list-style-type: none"> <li>•</li> <li>•</li> <li>•</li> </ul>	Observational Model: Cohort Time Perspective: Prospective Primary Purpose: to collect data end expand knowledge	Ocular GVHD occurs in 30-70% of patients after HSCT. oGVHD can severely impact patients' quality of life. This study aims to understand the population-based epidemiology of oGVHD and long-term ophthalmic outcomes.	18 years and older	<ul style="list-style-type: none"> <li>•</li> <li>•</li> </ul>	<ul style="list-style-type: none"> <li>• Graft Vs Host Disease</li> <li>• Haematological Malignancy</li> <li>• Cancer</li> </ul>
<b>A Safety Surveillance Study in Subjects with Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy</b>	NCT03167203	Enrolling by invitation	<ul style="list-style-type: none"> <li>•</li> <li>•</li> <li>•</li> </ul>	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	To evaluate late-onset adverse events in AIRM-sponsored clinical trial participants who underwent sub-retinal transplants of human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells.	18 years and older	<ul style="list-style-type: none"> <li>•</li> </ul>	<ul style="list-style-type: none"> <li>• Macular Degenerative Disease</li> </ul>